You are here
The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.
SBC: Zymeron Corporation Topic: CBD181004
Nerve agents exert their toxic effect by binding to and inactivating enzyme acetylcholinesterase, a key enzymatic regulator of cholinergic neurotransmission. The binding becomes irreversible after a varying amount of time with nerve agents and this aging process limits the treatment window of oxime reactivators. To enhance the current antidote treatment of nerve agent autoinjectors, a pyridostigmi ...SBIR Phase I 2019 Department of DefenseOffice for Chemical and Biological Defense
SBC: APATH, LLC Topic: CBD05119
The goal of this proposal is find novel combinations of approved drugs for the treatment and/or prevention of infection with filoviruses. Ebola and Marburg viruses, the only filoviruses, cause an acute hemorrhagic fever syndrome which has a high mortality rate and poses a significant bio-terrorism threat. There are currently no therapeutic agents available to treat filovirus infections and the de ...SBIR Phase I 2005 Department of DefenseOffice for Chemical and Biological Defense
SBC: MANNING APPLIED TECHNOLOGY Topic: CBD05112
Manning Applied Technology proposes to develop a handheld infrared spectrometer, ideally suited to detection of airborne chemical agents at and below permissible exposure limits. This approach offers unmatched sensitivity and specificity for detection of all types of chemical vapors. The instrument is modular, rugged, compact and highly sensitive. Volume pricing will be less than $1000 each. ...SBIR Phase I 2005 Department of DefenseOffice for Chemical and Biological Defense